China: The Pharma Deals Keep Coming

face
main_img

The latest from Chinese pharma, with dealmaking continuing apace. Featured this week are Zai Lab’s latest IPO listing in Hong Kong, InventisBio Series D financing round for small-molecule drugs, as well as Bioduro and Sundio’s merger to create one of the largest CRDMOs with operations in China and the US.

 

Zai Lab raises USD 825 million in HK IPO in secondary listing

https://www.caixinglobal.com/2020-09-29/biopharma-firm-zai-lab-raises-825-million-in-hong-kong-ipo-101611244.html

The Shanghai-based company’s Hong Kong shares rose 5.57% Tuesday after recording an 8.54% jump on their debut.

 

Hangzhou biotech Sumgen raises USD 32 million in Series B fundraising round

https://www.dealstreetasia.com/stories/sumgen-incarey-206663/

Sumgen develops antibody drugs for oncology and other severe diseases, with over 10 drug candidates currently in their pipeline.

 

Shanghai-based subsidiary of US drugmaker Biohaven Pharmaceutical, raised USD 60 million for APAC drug development

https://www.wsj.com/articles/neurological-drugmaker-bioshin-gets-60-million-to-tap-asia-pacific-market-11601334563

BioShin was established in 2018 to bring its drugs to markets globally.

 

InventisBio Completes $147 Million Round for Small-Molecule Drugs

http://www.chinabiotoday.com/articles/inventisbio-147-million

InventisBio, a Shanghai company developing novel small molecule drugs, completed a $147 million series D financing led by GL Ventures, a Hillhouse affiliate. It has four drug candidates in various clinical stage trials, including two registration trials.

 

Viva Biotech of Shanghai will pay $80 million to acquire fellow drug preclinical CRO SYNthesis Med Chem of Hong Kong

http://www.chinabiotoday.com/articles/viva-80-million-synthesis

Viva Biotech of Shanghai will pay $80 million to acquire fellow drug CRO SYNthesis Med Chem (Hong Kong). SYNthesis is a preclinical small molecule drug discovery CRO that specializes in high-end pharmaceutical chemistry and synthetic chemistry services. The company has labs in Suzhou, Shanghai and Australia. SYNthesis’ expertise is “downstream” from Viva’s structure-based drug discovery services that it offers to biopharma customers.

 

BioDuro and Sundia, two pre-clinical China-US CROs, have merged to form one of the largest CRDMOs that has operations in China and the US

http://www.chinabiotoday.com/articles/bioduro-merge-sundia

BioDuro and Sundia, two pre-clinical China-US CROs, have merged to form one of the largest CRDMOs with operations in China and the US. As part of the deal, Advent, a Boston  private equity investor, will lead a majority investment in Sundia. In early 2019, Advent acquired control of BioDuro, also via a majority investment. The new company, which will operate as BioDuro-Sundia, will offer drug discovery, development and manufacturing for both APIs and drug products.

 

Brazil’s Sao Paulo signs agreement with Sinovac for COVID-19 vaccine doses

https://www.channelnewsasia.com/news/world/brazil-sao-paulo-signs-agreement-sinovac-covid-19-vaccine-13165510

The government of Brazil’s Sao Paulo state signed a US$90 million contract on Wednesday (Sep 30) to receive 46 million doses of a potential vaccine from China’s Sinovac Biotech. Sao Paulo, Brazil’s most populous state, is one of the sites of Phase III clinical trials for the Sinovac vaccine conducted by the state’s Butantan Institute, a leading biomedical research centre.

 

Henlius granted exclusive development and commercialisation rights of HLX02 in the US and Canada to Accord

https://pipelinereview.com/index.php/2020100176058/Antibodies/Henlius-granted-exclusive-development-and-commercialisation-rights-of-HLX02-in-the-US-and-Canada-to-Accord.html

Shanghai Henlius Biotech, Inc. (2696.HK) announced the Company entered into a collaboration with Accord Healthcare Inc. (Accord US), according to which Henlius will grant an exclusive license to Accord US to develop and commercialise HLX02 – a Roche’s Herceptin® biosimilar – in the United States of America and Canada. With this collaboration, the commercialisation footprint of HLX02 has the potential to cover most of the global mainstream markets of biologics and to bring high-quality and affordable treatment options to global patients.

Add Your Comment


You must be logged in to post a comment.

Related Content

Latest Report